Malladi Drugs and Pharmaceuticals Limited

malladi.co.in

Malladi Drugs & Pharmaceuticals Ltd is one of India 's most tradition conscious and ethically sound Pharmaceutical Company. Malladi Drugs was founded in 1980 by late Mr. M L N Sastry, a pioneering microbiologist with expertise in fermentation technology. Malladi is the leading manufacturer of Active Pharmaceutical Ingredients (API) in the Cough and Cold segment along with a dominant presence in other therapeutic segments like Anti-histamines, Anti-convulsants, Anti-depressants and Anxiolytics (CNS) of the global pharmaceutical industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

VIRPAX PHARMACEUTICALS ENTERS INTO CRADA WITH THE U.S. ARMY INSTITUTE OF SURGICAL RESEARCH

Virpax® Pharmaceuticals, Inc. | May 06, 2022

news image

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement with the U.S. Army Institute of Surgical Research to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the woun...

Read More

Business Insights, PHARMACY MARKET

EVERSANA AND XSPRAY PHARMA PARTNERS FOR US LAUNCH OF DASYNOC

EVERSANA | February 24, 2023

news image

On February 23, 2023, Xspray Pharma AB announced that it has signed an agreement with EVERSANA to aid the launch and commercialization of its innovative cancer therapy Dasynoc for treating chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL) in the United States. Xspray Pharma will maintain financial and strategic control while granting EVERSANA exclusive commercialization access to support the second-half 2023 launch of Dasynoc. Dasynoc, if FDA approved, will be a new treatme...

Read More

Business Insights

SAUDI MINISTRY OF INVESTMENT AND INSILICO MEDICINE SIGN AGREEMENT TO EXPAND REGION’S BIOTECHNOLOGY CAPABILITIES

Insilico Medicine | September 15, 2022

news image

Saudi Arabia’s Ministry of Investment and clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine have signed a memorandum of understanding (MoU) to support the development of a robust AI-driven biotech industry in the Kingdom. The agreement was signed during the Global AI Summit, held from the 13th through the 15th of September in Riyadh, which featured over 200 speakers representing 90 countries discussing the future of AI, including Insilico Medicine ...

Read More

Business Insights, PHARMA TECH

AVITA ACQUIRES Q CARE PLUS, RENAMES IT AVITA CARE SOLUTIONS

Avita Care Solutions | January 10, 2023

news image

PMQ Investors, LLC, the parent company of Avita, has acquired Q Care Plus, Inc. This community-focused care management solution offers stigma-free access to care via telehealth, focusing on telePrEP services. Meanwhile, the terms and conditions of the deal are yet to be revealed. "Bringing Avita and Q Care Plus together comes at a time when reducing health inequities among underserved populations is more critical than ever," said Avita Chief Executive Offi...

Read More
news image

Business Insights

VIRPAX PHARMACEUTICALS ENTERS INTO CRADA WITH THE U.S. ARMY INSTITUTE OF SURGICAL RESEARCH

Virpax® Pharmaceuticals, Inc. | May 06, 2022

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement with the U.S. Army Institute of Surgical Research to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the woun...

Read More
news image

Business Insights, PHARMACY MARKET

EVERSANA AND XSPRAY PHARMA PARTNERS FOR US LAUNCH OF DASYNOC

EVERSANA | February 24, 2023

On February 23, 2023, Xspray Pharma AB announced that it has signed an agreement with EVERSANA to aid the launch and commercialization of its innovative cancer therapy Dasynoc for treating chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL) in the United States. Xspray Pharma will maintain financial and strategic control while granting EVERSANA exclusive commercialization access to support the second-half 2023 launch of Dasynoc. Dasynoc, if FDA approved, will be a new treatme...

Read More
news image

Business Insights

SAUDI MINISTRY OF INVESTMENT AND INSILICO MEDICINE SIGN AGREEMENT TO EXPAND REGION’S BIOTECHNOLOGY CAPABILITIES

Insilico Medicine | September 15, 2022

Saudi Arabia’s Ministry of Investment and clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine have signed a memorandum of understanding (MoU) to support the development of a robust AI-driven biotech industry in the Kingdom. The agreement was signed during the Global AI Summit, held from the 13th through the 15th of September in Riyadh, which featured over 200 speakers representing 90 countries discussing the future of AI, including Insilico Medicine ...

Read More
news image

Business Insights, PHARMA TECH

AVITA ACQUIRES Q CARE PLUS, RENAMES IT AVITA CARE SOLUTIONS

Avita Care Solutions | January 10, 2023

PMQ Investors, LLC, the parent company of Avita, has acquired Q Care Plus, Inc. This community-focused care management solution offers stigma-free access to care via telehealth, focusing on telePrEP services. Meanwhile, the terms and conditions of the deal are yet to be revealed. "Bringing Avita and Q Care Plus together comes at a time when reducing health inequities among underserved populations is more critical than ever," said Avita Chief Executive Offi...

Read More

Resources

resource image

Pharma Tech

ValGenesis e-Logbook

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us